BCM
OCUL icon

BlueCrest Capital Management’s Ocular Therapeutix OCUL Stock Holding History

BlueCrest Capital Management’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-16,893
Closed -$116K – 1252
2018
Q3 		$116K Buy
+16,893
New +$106K ﹤0.01% 1369

Other funds holding OCUL

SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Man Group
Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DAM
Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return
SHI
SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return

BlueCrest Capital Management's OCUL Position: Q4 2018 in Review

BlueCrest Capital Management sold out of Ocular Therapeutix (OCUL) in Q4 2018, closing a stake of 16,893 shares — an estimated $116K sold.

BlueCrest Capital Management first reported a position in OCUL in Q3 2018 and held it in 1 quarter. The position peaked at $116K in Q3 2018. 69 funds tracked by Wall St. Rank hold OCUL as of Q4 2018.

  • BlueCrest Capital Management reported no remaining Ocular Therapeutix position as of Q4 2018 after selling out during the quarter.
  • BlueCrest Capital Management sold 16,893 Ocular Therapeutix shares in Q4 2018, an estimated $116K.
  • BlueCrest Capital Management first reported a position in Ocular Therapeutix in Q3 2018 and held it in 1 quarter.
  • BlueCrest Capital Management's Ocular Therapeutix position peaked at $116K in Q3 2018.
  • 69 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q4 2018.

Based on BlueCrest Capital Management's 13F filing for Q4 2018, filed 14 Feb 2019.